TAIMEI TECH (02576) announced that on December 24, 2025 (after trading hours), the company (as a limited partner), TAIMEI Research (as a limited partner), Jiaxing Industrial Investment (as a limited partner), Mr. Lu Gaofeng (as a limited partner), Ms. Lu Haixiao (as a limited partner), Ms. Chen Guojuan (as a limited partner), and Kaifeng TAIMEI (as a general partner) entered into a partnership agreement to establish a partnership. The total initial capital contribution by all partners will be RMB227.27 million, with TAIMEI TECH, TAIMEI Research, Jiaxing Industrial Investment, Mr. Lu Gaofeng, Ms. Lu Haixiao, Ms. Chen Guojuan, and Kaifeng TAIMEI contributing RMB70 million, RMB30 million, RMB100 million, RMB10 million, RMB5 million, RMB10 million, and RMB2.27 million, respectively. The partnership will prioritize investments in companies located in the Jiaxing Economic and Technological Development Zone.
The board believes that by establishing the partnership, the company can deeply engage in innovative drug pipeline research and development. This will enable TAIMEI TECH to standardize and modularize its digital and intelligent pharmaceutical R&D solutions for early-to-growth-stage innovative drug pipelines, thereby gaining opportunities to share in the excess returns from successful drug development and expand its industry footprint. Additionally, by holding pipeline interests through the partnership and participating in early-stage clinical trials, the company can secure key segments of the industry value chain while avoiding the complexity and long-cycle risks associated with traditional equity investments. Efficient exits can be achieved through pipeline transfers or sales, enabling rapid capital turnover and value realization.
Comments